Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
PLoS One. 2011;6(8):e23886. doi: 10.1371/journal.pone.0023886. Epub 2011 Aug 25.
Glycine receptors (GlyRs) are transmitter-gated anion channels of the Cys-loop superfamily which mediate synaptic inhibition at spinal and selected supraspinal sites. Although they serve pivotal functions in motor control and sensory processing, they have yet to be exploited as drug targets partly because of hitherto limited possibilities for allosteric control. Endocannabinoids (ECs) have recently been characterized as direct allosteric GlyR modulators, but the underlying molecular sites have remained unknown. Here, we show that chemically neutral ECs (e.g. anandamide, AEA) are positive modulators of α(1), α(2) and α(3) GlyRs, whereas acidic ECs (e.g. N-arachidonoyl-glycine; NA-Gly) potentiate α(1) GlyRs but inhibit α(2) and α(3). This subunit-specificity allowed us to identify the underlying molecular sites through analysis of chimeric and mutant receptors. We found that alanine 52 in extracellular loop 2, glycine 254 in transmembrane (TM) region 2 and intracellular lysine 385 determine the positive modulation of α(1) GlyRs by NA-Gly. Successive substitution of non-conserved extracellular and TM residues in α(2) converted NA-Gly-mediated inhibition into potentiation. Conversely, mutation of the conserved lysine within the intracellular loop between TM3 and TM4 attenuated NA-Gly-mediated potentiation of α(1) GlyRs, without affecting inhibition of α(2) and α(3). Notably, this mutation reduced modulation by AEA of all three GlyRs. These results define molecular sites for allosteric control of GlyRs by ECs and reveal an unrecognized function for the TM3-4 intracellular loop in the allosteric modulation of Cys-loop ion channels. The identification of these sites may help to understand the physiological role of this modulation and facilitate the development of novel therapeutic approaches to diseases such as spasticity, startle disease and possibly chronic pain.
甘氨酸受体(GlyRs)是 Cys 环超家族的递质门控阴离子通道,在脊髓和选定的脑区发挥突触抑制作用。尽管它们在运动控制和感觉处理中具有关键作用,但由于迄今为止对别构控制的可能性有限,它们尚未被用作药物靶点。内源性大麻素(ECs)最近被确定为直接的别构甘氨酸受体调节剂,但潜在的分子靶点仍然未知。在这里,我们表明,化学中性的 ECs(例如,大麻素,AEA)是α(1)、α(2)和α(3)甘氨酸受体的正调节剂,而酸性 ECs(例如,N-花生四烯酰-甘氨酸;NA-Gly)增强α(1)甘氨酸受体,但抑制α(2)和α(3)。这种亚基特异性使我们能够通过对嵌合体和突变体受体的分析来识别潜在的分子靶点。我们发现,细胞外环 2 中的丙氨酸 52、跨膜(TM)区域 2 中的甘氨酸 254 和细胞内赖氨酸 385 决定了 NA-Gly 对α(1)甘氨酸受体的正调节。在α(2)中连续取代非保守的细胞外和 TM 残基将 NA-Gly 介导的抑制转化为增强。相反,突变 TM3 和 TM4 之间细胞内环内的保守赖氨酸减弱了 NA-Gly 对α(1)甘氨酸受体的增强作用,而不影响对α(2)和α(3)的抑制。值得注意的是,这种突变降低了 AEA 对所有三种甘氨酸受体的调制。这些结果定义了 EC 对甘氨酸受体别构控制的分子靶点,并揭示了 TM3-4 细胞内环在 Cys 环离子通道别构调节中的未被认识的功能。这些位点的鉴定可能有助于理解这种调节的生理作用,并促进开发治疗痉挛、惊吓疾病和可能的慢性疼痛等疾病的新疗法。